Black Diamond Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
10b5-1 Plans
From time to time, our officers (as defined in Rule 16a–1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended March 31, 2024, our officers and directors took the following actions with respect to 10b5-1 trading arrangements:
On March 28, 2024, Fang Ni, our Chief Business Officer and Chief Financial Officer, entered into a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Ni 10b5-1 Plan). The Ni 10b5-1 Plan is scheduled to commence on June 29, 2024, and will run through June 29, 2025. The aggregate maximum number of shares of common stock that may be sold pursuant to the Ni 10b5-1 Plan is up to 40,470 shares.
On March 27, 2024, Brent Hatzis-Schoch, our Chief Operating Officer and General Counsel, entered into a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Hatzis-Schoch 10b5-1 Plan). The Hatzis-Schoch 10b5-1 Plan is scheduled to commence on July 1, 2024, and will run through July 1, 2025. The aggregate maximum number of shares of common stock that may be sold pursuant to the Hatzis-Schoch 10b5-1 Plan is up to 72,400 shares.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.